E. J. ter Borg

Measurement of increases in anti‐double‐stranded dna antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus

E. J. ter Borg, Gerda Horst, E. J. Hummel et al. · Arthritis & Rheumatism · 1990 · 561 citations

Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)

Suzanne Verstappen, Johannes W. G. Jacobs, M. J. van der Veen et al. · Annals of the Rheumatic Diseases · 2007 · 555 citations · Full text

Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial

J. W. J. Bijlsma, Paco M J Welsing, Thasia Woodworth et al. · The Lancet · 2016 · 238 citations

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +8

The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long term observation

Hendrika Bootsma, Peter E. Spronk, E. J. ter Borg et al. · Annals of the Rheumatic Diseases · 1997 · 114 citations · Full text

Five‐year followup of rheumatoid arthritis patients after early treatment with disease‐modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year

Suzanne Verstappen, Johannes W. G. Jacobs, J. W. J. Bijlsma et al. · Arthritis & Rheumatism · 2003 · 112 citations